Clinical Trials Logo

mCRPC clinical trials

View clinical trials related to mCRPC.

Filter by:

NCT ID: NCT06056791 Recruiting - Cancer Clinical Trials

Study of INKmune in Patients With mCRPC (CaRe Prostate)

CaRe
Start date: November 30, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, phase I/IIa dose escalation and expansion study of INKmune in men with mCRPC. INKmune is administered to patients intravenously over three doses, at least one-week apart. The study will consist of two stages.

NCT ID: NCT05547061 Recruiting - Prostate Cancer Clinical Trials

A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy

Start date: April 12, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This clinical trial is an open-label, single-arm, multi-center, escalation (Phase 1 Part B only), rater-blind (Phase 2 only), phase 1/2 trial to evaluate the diagnostic validity/safety of Ga-68-NGUL and efficacy/safety of Lu-177-DGUL on the anti-tumor activity that aims to simultaneously evaluate diagnostic and therapeutic validity.

NCT ID: NCT05413850 Recruiting - Prostate Cancer Clinical Trials

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Start date: July 20, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate cancer.

NCT ID: NCT05383079 Recruiting - Prostate Cancer Clinical Trials

Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men With Metastatic Castration-Resistant Prostate Cancer

AlphaBet
Start date: September 13, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This clinical trial will evaluate the safety of Radium-223 in combination with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer: Phase I/II study

NCT ID: NCT05340374 Recruiting - Clinical trials for Metastatic Castration-resistant Prostate Cancer

Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer

LuCAB
Start date: July 14, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This clinical trial will evaluate the safety of Cabazitaxel in combination with 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer.

NCT ID: NCT04822961 Not yet recruiting - mCRPC Clinical Trials

Senaparib in mCRPC Patients With Homologous Recombination Repair Gene Alterations After Docetaxel Treatment

Start date: December 31, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Senaparib in metastatic castration-resistant prostate cancer (mCRPC) patients with homologous recombination repair (HRR) gene alterations after docetaxel treatment

NCT ID: NCT04729114 Recruiting - Prostate Cancer Clinical Trials

Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer

Start date: June 14, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase 1/2a, open-label, multicenter study of intramuscular (i.m.) PRL-02 depot in participants with advanced prostate cancer.

NCT ID: NCT04145375 Enrolling by invitation - mCRPC Clinical Trials

Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol

Start date: November 12, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol

NCT ID: NCT03851640 Recruiting - mCRPC Clinical Trials

A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Start date: April 12, 2019
Phase: Phase 3
Study type: Interventional

The study primary objective is to evaluate the effect of HC-1119 soft capsules versus placebo on overall survival (OS) in mCRPC patients who have failed or become intolerant to the treatments with both abiraterone acetate and docetaxel, or who are not suitable for docetaxel treatment.

NCT ID: NCT03395197 Active, not recruiting - mCRPC Clinical Trials

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

TALAPRO-2
Start date: December 18, 2017
Phase: Phase 3
Study type: Interventional

This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.